Danish Novo Nordisk profit surges

January 31, 2013

Danish pharmaceutical company Novo Nordisk A/S on Thursday reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide begin to approve its latest range of insulin products.

The world's largest insulin maker said net profit was 5.7 billion kroner ($1 billion) in the three-month period with revenue increasing 16 percent to 21 billion from 18 billion kroner a year earlier. Net profit in the full-year grew 25 percent to 21.4 billion kroner with sales of 78 billion kroner.

Chief Executive Lars Rebien Soerensen described 2012 as "another year with strong results," driven by successful insulin sales.

The company said it expects revenue growth of 8 to 11 percent this year with operating profit increasing some 10 percent.

Novo Nordisk, which said it was the world leader in sales of diabetes care products, said sales grew 21 percent last year compared to a year earlier to 60 billion kroner. It also claims the global top spot in the insulin market with a share of 49 percent.

The company said that Novo Nordisk Inc. was one of several hormone therapy product manufacturers in the United States which are defendants in product liability lawsuits related to hormone therapy products involving 38 people. It said it does not expect the pending claims to have a material impact on its financial position, operating profit and cash flow.

The company employed some 35,000 people at the end of 2012, up from 33,000 a year earlier.

Novo Nordisk's share price was up slightly at 1,027.00 kroner in afternoon trading in Copenhagen.

Explore further: Diabetes drugs helps boost Novo Nordisk in Q2

shares

Related Stories

Diabetes drugs helps boost Novo Nordisk in Q2

August 9, 2012
(AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 29 percent in the second quarter of 2012, chiefly spurred by strong sales of its new diabetes drugs.

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.